company background image
ALA logo

Arovella Therapeutics ASX:ALA Stock Report

Last Price

AU$0.14

Market Cap

AU$141.8m

7D

3.8%

1Y

200.0%

Updated

14 Jun, 2024

Data

Company Financials

Arovella Therapeutics Limited

ASX:ALA Stock Report

Market Cap: AU$141.8m

ALA Stock Overview

A biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally.

ALA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Arovella Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arovella Therapeutics
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.18
52 Week LowAU$0.042
Beta-0.25
1 Month Change22.73%
3 Month Change-10.00%
1 Year Change200.00%
3 Year Change275.00%
5 Year Change35.00%
Change since IPO-96.91%

Recent News & Updates

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Shareholder Returns

ALAAU PharmaceuticalsAU Market
7D3.8%1.7%-0.9%
1Y200.0%59.5%8.6%

Return vs Industry: ALA exceeded the Australian Pharmaceuticals industry which returned 59.5% over the past year.

Return vs Market: ALA exceeded the Australian Market which returned 8.6% over the past year.

Price Volatility

Is ALA's price volatile compared to industry and market?
ALA volatility
ALA Average Weekly Movement14.7%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.4%
10% least volatile stocks in AU Market3.2%

Stable Share Price: ALA has not had significant price volatility in the past 3 months.

Volatility Over Time: ALA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1999n/aMichael Bakerwww.arovella.com

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London.

Arovella Therapeutics Limited Fundamentals Summary

How do Arovella Therapeutics's earnings and revenue compare to its market cap?
ALA fundamental statistics
Market capAU$141.77m
Earnings (TTM)-AU$10.23m
Revenue (TTM)AU$1.97m

72.0x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALA income statement (TTM)
RevenueAU$1.97m
Cost of RevenueAU$22.86k
Gross ProfitAU$1.95m
Other ExpensesAU$12.18m
Earnings-AU$10.23m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0097
Gross Margin98.84%
Net Profit Margin-519.20%
Debt/Equity Ratio0%

How did ALA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.